Neoadjuvant Regorafenib Plus Durvalumab (MEDI4736) in Patients with High-Risk Hepatocellular Carcinoma

Protocol No
ACCRU-GI-1920-HCC
Phase
II
Summary

The purpose of this research study is to find out what effects, good and/or bad, the combination
of Regorafenib and Durvalumab has on you and your liver cancer.

Durvalumab is approved by the FDA for the treatment of many types of cancer, but its use in
this study is investigational. Regorafenib is approved by the FDA for the treatment of your type
of cancer, but its use in combination with Durvalumab in this study is investigational.

We don't know if this study will help you. Your condition may get better, but it could stay the
same or even get worse. We hope the information from this study will help us develop a better
treatment for liver cancer in the future.

Description
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL